Ananda Pharma PLC - Result of Annual General Meeting

Announcement provided by

26/08/2025 14:43

RNS Number : 7279W

Ananda Pharma PLC

26 August 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU, WHICH IS PART OF UNITED KINGDOM DOMESTIC LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

A logo with blue and green dots Description automatically generated

26 August 2025

ANANDA PHARMA PLC

("Ananda" or the "Company")

Result of Annual General Meeting

Ananda Pharma plc (AQSE: ANA, OTC: ANANF), a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, is pleased to announce that at the Annual General Meeting of the Company held earlier today all resolutions were duly passed by shareholders.

Proxy votes received ahead of the meeting were as follows:

Resolution Number	Resolution Name	% of Votes For	% of Votes Against	Total Votes Cast (Excluding Withheld)	Number of Votes Withheld
01	Report and Financial Statements	99.997	0.003	1,614,787,696	0
02	Charles Morgan	99.996	0.004	1,614,787,696	0
03	Jeremy Sturgess-Smith	99.996	0.004	1,614,787,696	0
04	Stuart Piccaver	99.996	0.004	1,614,787,696	0
05	Clive Page	99.996	0.004	1,581,454,363	0
06	Melissa Sturgess	99.997	0.003	1,614,787,696	0
07	John Treacy	99.996	0.004	1,614,787,696	0
08	Re-appoint Auditors	99.997	0.003	1,614,787,696	0
09	Allotment of Securities	99.996	0.004	1,614,787,696	0
10	Pre-emption Rights	99.963	0.0037	1,614,787,612	84

About Ananda Pharma

Ananda Pharma (AQSE: ANA) is a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, including epilepsy (trials funded by NHS England and NIHR), endometriosis (funded by NHS Scotland) and chemotherapy pain (funded by NIHR). The Company is led by successful entrepreneurs and is working with a team of world-class scientists, including globally respected Key Opinion Leaders at the University of Edinburgh, Great Ormond Street Hospital for Children and University College London.

For more information, please visit our website:

To stay up to date with Ananda's news please follow our social media channels:

· Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93

· Instagram: https://www.instagram.com/anandapharmaplc/

· LinkedIn: https://www.linkedin.com/company/anandapharma

· X: https://twitter.com/AnandaPlc

· Investor Meet Company: https://www.investormeetcompany.com/ananda-pharma-plc/register-investor

-Ends-

For the purposes of UK MAR, the Directors of the Company accept responsibility for the contents of this announcement.

ANANDA PHARMA PLC	+44 (0)7463 686 497
	ir@anandapharma.co.uk
Chief Executive Officer
Melissa Sturgess

Finance Director
Jeremy Sturgess-Smith

SP ANGEL CORPORATE FINANCE LLP

Corporate Broking	+44 (0)20 3470 0534
Abigail Wayne	Abigail.wayne@spangel.co.uk
Rob Rees	Rob.ress@spangel.co.uk
Corporate Finance	+44 (0)20 3470 0470
Richard Morrison
Josh Ray

VIRIDIAN CAPITAL ADVISORS (US) Scott Greiper	+1 (646) 330-0704 sgreiper@viridianca.com
YELLOW JERSEY PR Sarah MacLeod Charles Goodwin Zara McKinlay	+44 (0)20 3004 9512 ananda@yellowjerseypr.com

https://investors.anandapharma.co.uk/link/PljVae

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXEADPKADNSEFA]]>

ANA announcements All announcements